A Phase 4 interventional study of Eye injection (Mydrane) and eye drops (Phenylephrin) in Cataract, sponsored by Medical University of Graz. Completed at 1 site in Austria. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-10-19.
Sponsored by Medical University of Graz · Phase 4, Interventional, and Treatment
The primary aim of the study is to compare the effectiveness of the intracameral application of Mydrane® (standardized combination of Tropicamide 0.02%, Phenylephrine 0.31% and Lidocaine 1%) with the preoperative topical application (Tropicamide 0.5% and Phenylephrine 10%). To evaluate the steadiness of the dilating effect on the pupil, the ratio of eyes without necessity for further pupil dilating procedures to perform the capsulorhexis is assessed.
1,629 studies on the registry are indexed under Cataract; 235 are open to participants now.
This study's enrollment of 42 is below the median of 79 across 1,092 interventional studies indexed under Cataract.
Browse Cataract studies →Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mydrane, Tropicamid 0,02%, Phenylephrine 0,31%, Lidocain 1%, injection solution
Drug: Eye injection (Mydrane)
Phenylephrine 10% and Tropicamid 0,5% eye drops
Drug: eye drops (Phenylephrin) · Drug: eye drops (Tropicamid)
Mydrane 0.2 mg/ml + 3.1 mg/ml + 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride
Also known as: Mydrane
Phenylephrine 10%
Also known as: Minims
Tropicamid 0,5%
Also known as: Agepha
pupil dilating
The frequency of the feasibility of capsulorhexis without additional pupil dilating actions
Time frame: during first and second surgery: a maximum of four weeks between first and second surgery
subjective highest intraoperative pain
Highest intraoperative pain visualized on a visual analogue scale (VAS) asked by a questionnaire, with the minimum 1 and maximum 10 , where higher scores mean a worse outcome
Time frame: after first and second surgery: a maximum of four weeks between first and second surgery
subjective perception of anesthetic procedures
perception of anesthetic procedures visualized on a visual analogue scale (VAS) asked by a questionnaire, with the minimum 1 and maximum 10 , where higher scores mean a worse outcome
Time frame: after first and second surgery: a maximum of four weeks between first and second surgery
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.